Alerts
Other content recommended for you
- Incremental benefits of novel pharmaceuticals in the UK: a cross-sectional analysis of NICE technology appraisals from 2010 to 2020
- Cost-effectiveness of implantable cardiac devices in patients with systolic heart failure
- Cost-utility of direct transfer to angiography suite (DTAS) bypassing conventional imaging for patients with acute ischemic stroke in Spain: results from the ANGIOCAT trial
- Generating evidence for new high-risk medical devices
- Utilisation, expenditure and cost-effectiveness of cystic fibrosis drugs in Ireland: a retrospective analysis of a national pharmacy claims database
- Current challenges for assessing the long-term clinical benefit of cancer immunotherapy: a multi-stakeholder perspective
- Quality-adjusted life years
- NICE is dead; long live NICE
- Industry funding of patient organisations in the UK: a retrospective study of commercial determinants, funding concentration and disease prevalence
- How to avoid unfair discrimination against disabled patients in healthcare resource allocation